Pharmaceuticals, Biotechnology and Life Sciences
In total, 19 abstracts were presented on Baxter’s therapy options New HDx data supports growing evidence that removing a wider…
DEERFIELD, Ill. & MARCY L’ÉTOILE, France–(BUSINESS WIRE)–Baxter International Inc. (NYSE:BAX), a global leader in acute care, and bioMérieux, a world…
Baxter International has completed the acquisition of two hemostat and sealant products from Mallinckrodt plc. RECOTHROM Thrombin topical (Recombinant) is…
Baxter International has announced the U.S. Food and Drug Administration (FDA) approval of Bivalirudin in 0.9 percent Sodium Chloride Injection…
Drugmaker Shire Plc clinched its six-month pursuit of Baxalta International Inc on Monday with an agreed $32 billion (22 billion pound) cash and stock offer, catapulting it to a leading position in treating rare diseases.